Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and Diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 2, 2012, Pages 425-443

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Fat metabolism; Growth; Growth hormone; Insulin resistance

Indexed keywords

CORTICOSTEROID; GONADOTROPIN ANTAGONIST; GONADOTROPIN RECEPTOR; GROWTH HORMONE; INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN B; SOMATOMEDIN C;

ARTHRALGIA; CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EDEMA; ENZYME ACTIVITY; ENZYME REGULATION; GENE; GENETIC DISORDER; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; IGF 1 GENE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DIETARY FATS; DIETARY PROTEINS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLIC SYNDROME X; MICE; POLYMORPHISM, GENETIC; RATS; SEVERITY OF ILLNESS INDEX;

EID: 84861982113     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.04.017     Document Type: Review

References (104)

1. Bayne M.L., Applebaum J., Chicchi G.G., et al. The roles of tyrosines 24, 31, and 60 in the high-affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor. J Biol Chem 1990, 265:15648.
2. Clemmons D.R., Dehoff M.H., Busby W.H., et al. Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. Endocrinology 1992, 131:890.
3. Ullrich A., Gray A., Tam A.W., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986, 5:2503-2512.
4. Brooks A.J., Waters M.J. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010, 6:515-525.
5. Isley W.L., Underwood L.E., Clemmons D.R. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 1983, 71:175-182.
6. Underwood L.E., Thissen J.P., Lemozy S., et al. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994, 42:145-151.
7. Yakar S., Liu J.L., Stannard B., et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96:7324-7329.
8. Phillips L.S., Pao C.I., Villafuerte B.C. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucleic Acid Res Mol Biol 1998, 60:195-265.
9. Bereket A., Lang C.H., Blethen A.L., et al. Effect of insulin on the insulin-like growth factor system in children with new onset dependent diabetes. J Clin Endocrinol Metab 1995, 80:1312-1317.
10. Lowe W.L., Adamo M., Werner H., et al. Regulation by fasting of insulin-like growth factor I and its receptor: effects on gene expression and binding. J Clin Invest 1989, 84:619-626.
11. Holly J., Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinol 2006, 83:154-160.
12. Boisclair Y.R., Rhoads R.P., Ueki I., et al. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001, 170:63-70.
13. Chen J.W., Hojlund K., Beck-Nielsen H., et al. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J Clin Endocrinol Metab 2005, 90:366-371.
14. Myers M.J., White M.F. Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol 1996, 36:615.
15. Ning J., Clemmons D.R. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 2010, 24:1218-1229.
16. Adamo M.L., Farrar R.P. Resistance training, and IGF involvement in the maintenance of muscle mass during the aging process. Ageing Res Rev 2006, 5:310-331.
17. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005, 37:1974-1984.
18. Dehoux M., Van Beneden R., Pasko N., et al. Role of the insulin-like growth factor-I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinol 2004, 245:4806-4812.
19. O'Connor J.C., McCusker R.H., Strle K., et al. Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol 2008, 252:91-110.
20. Mauras N., Beaufrere B. rhIGF-I enhances whole body protein anabolism and significantly diminishes the protein-catabolic effects of prednisone in humans, without a diabetogenic effect. J Clin Endocrinol Metab 1995, 80:869-874.
21. Mauras N., Martinez V., Rini J., et al. Recombinant human IGF-I has significant anabolic effects in adults with GH receptor deficiency: studies on protein, glucose and lipid metabolism. J Clin Endocrinol Metab 2000, 85:3036-3042.
22. Mauras N., O'Brien K.O., Welch S., et al. IGF-I and GH treatment in GH deficient humans: differential effects on protein, glucose, lipid and calcium metabolism. J Clin Endocrinol Metab 2000, 85:1686-1694.
23. Debroy M.A., Wolf S.E., Zhang X.J., et al. Anabolic effect of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma 1999, 47:904-910.
24. Fouque D., Peng S.C., Kopple J.D. Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients. Kidney Int 1995, 47:876-883.
25. Mauras N., Hayes V., Welch S., et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics strength and adiposity. J Clin Endocrinol Metab 1998, 83:1886-1892.
26. Scavo L.M., Karase M., Murry M., et al. Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab 2004, 84:3543-3553.
27. DiGirolamo M., Eden S., Enberg O., et al. Specific binding of human growth hormone but not insulin-like growth factors by human adipocytes. FEBS Lett 1986, 205:15-19.
28. Mauras N., O'Brien K.O., Welch S., et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000, 85:1686-1694.
29. Fernandez A.M., Kim J.K., Yakar S., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001, 15:1926-1934.
30. Heron-Milhavet L., Haluzik M., Yakar S., et al. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinol 2004, 145:4667-4676.
31. Yuen K.C., Dunger D.B. Therapeutic aspect of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 2007, 9:11-22.
32. del Rincon J.P., Lida K., Gaylinn B.D., et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism of growth hormone-mediated insulin resistance. Diabetes 2007, 56:1638-1646.
33. Barbour L.A., Mizanoor Rahman S., Gurevich I., et al. Increased p85alpha potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 2005, 280:37489-37494.
34. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004, 14:337-375.
35. Furling D., Marette A., Puymirat J. Insulin-like growth factor I circumvents defective insulin action in human myotonic dystrophy skeletal cells. Endocrinol 1999, 140:4244-4250.
36. Henry R.R., Abrams L., Nikoulina S., et al. Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Diabetes 1995, 44:936-946.
37. Pennisi P., Gavrilova O., Setser-Portas J., et al. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinol 2006, 147:L2619-L2630.
38. LeRoith D., Kim H., Fernandez A.M., et al. Inactivation of muscle insulin and IGF-I receptors and insulin responsiveness. Curr Opin Clin Nutr Metab Care 2002, 5:371-375.
39. Yakar S., Liu J.L., Fernandez A.M., et al. Liver-specific Igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50:1110-1118.
40. O'Connell T., Clemmons D.R. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 2002, 87:4356-4360.
41. Simpson H., Savine R., Sonksen P., et al. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 2002, 12:12-33.
42. Brabant G., von zur Muhlen A., Wuster C., et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003, 60:53-60.
43. Leung K.C., Ho K.K. Measurement of growth hormone, insulin-like growth factor I and their binding proteins: the clinical aspects. Clin Chim Acta 2001, 313:119-123.
44. Brismar K., Hilding A., Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res 1995, 6:449-456.
45. Arafat A.M., Weickert M.O., Frystyk J., et al. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 2009, 94:5093-6101.
46. Lukanova A., Soderberg S., Stattin P., et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 2002, 13:509-516.
47. Maccario M., Tassone F., Gauna C., et al. Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH. Eur J Endocrinol 2001, 144:251-256.
48. Schneider H.J., Saller B., Klotsche J., et al. Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 2006, 154:699-706.
49. Saydah S., Ballard-Barbash R., Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control 2009, 20:1309-1316.
50. Martha S., Pantam N., Thungathurthi S., et al. Study of insulin resistance in relation to serum IGf-I levels in subjects with different degrees of glucose tolerance. Int J Diabetes Dev Ctries 2008, 28:54-59.
51. Dunger D., Yuen K., Ong K. Insulin-like growth factor I and impaired glucose tolerance. Horm Res 2004, 1:10-17.
52. Efstratiadis G., Tiaousis G., Athyros V.G., et al. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006, 57:303-311.
53. Maes M., Ketelslegers J.M., Underwood L.E. Low circulating somatomedin-C/insulin-like growth factor I in insulin-dependent diabetes and malnutrition: growth hormone receptor and post-receptor defects. Acta Endocrinol Suppl 1986, 279:86-92.
54. Hanaire-Broutin H., Sallerin-Caute B., Poncet M.F., et al. Insulin therapy and GH-IGF-I axis disorders in diabetes: impact and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabetes Metab 1996, 22:245-250.
55. Scheiwiller E., Guler H.P., Merryweather J., et al. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 1986, 323:169-171.
56. Sandhu M.S. Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 2005, 9:44-54.
57. Frystyk J., Skjaerbaek C., Vestbo E., et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999, 15:314-322.
58. Lewitt M.S., Hilding A., Brismar K., et al. IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur J Endocrinol 2010, 163:233-242.
59. Lewitt M.S., Denyer G.S., Cooney G.J., et al. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinol 1991, 129:2254-2256.
60. Heald A.H., Haushal K., Siddals K.W., et al. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006, 114:371-376.
61. Wheatcroft S.B., Kearney M.T., Shah A.M., et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007, 56:285-294.
62. Bang P., Brismar K., Rosenfeld R.G. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150 kDa ternary complex. J Clin Endocrinol Metab 1994, 78:1119-1127.
63. Cheetham T.D., Holly J.M., Baxter R.C. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1998, 157:81-87.
64. Petersson U., Ostegrn C.J., Brudin L., et al. Low levels of insulin-like growth factor binding protein-1 (IGFBP-1 ) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes Metab 2009, 35:198-205.
65. Heald A.H., Anderson S.G., Ivison F., et al. C-reactive protein and the insulin-like growth factor (IGF) system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 2003, 170:79-86.
66. Tong P.C., Ho C.S., Yeung V.T., et al. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab 2005, 90:6418-6423.
67. Sakai K., D'Ercole A.J., Murphy L.J., et al. Physiological differences in insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation in IGFBP-1 transgenic mice. Diabetes 2001, 50:32-38.
68. Wabisch M., Blum W.F., Muche R., et al. Insulin-like growth factors and their binding proteins before and after weight loss and their associations with hormonal and metabolic parameters in obese adolescent girls. Int J Obes Relat Metab Disord 1996, 20:1073-1080.
69. Reinehr T., Kleber M., Toschke A.M., et al. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int J Pediatr Obes 2011, 6(3-4):236-243.
70. Jacob R.J., Sherwin R.S., Greenawalt K., et al. Simultaneous insulinlike growth factor I and insulin resistance in obese Zucker rats. Diabetes 1992, 41:691-697.
71. Sandhu M.S., Heald A.H., Gibson J.M., et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002, 359:1740-1745.
72. Qiu C., Vadachkoria S., Meryman L., et al. Maternal plasma concentrations of IGF-1, IGFBP-1, and C-peptide in early pregnancy and subsequent risk of gestational diabetes mellitus. Am J Obstet Gynecol 2005, 193:1691-1697.
73. Rajpathak S.N., McGinn A.P., Strickler H.D., et al. Insulin-like growth factor (IGF) axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 2008, 19:166-173.
74. Heald A.H., Karvestedt L., Anderson S.G., et al. Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes. Am J Med 2006, 119:167. e9-15.
75. Arends N., Johnston L., Hokken-Koelega A., et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol 2002, 87:2720.
76. Vaessen N., Hautink P., Janssen J.A., et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001, 50:637-642.
77. Eerligh P., Roep B.O., Giphart M.J., et al. Insulin-like growth factor 1 promoter polymorphism influences insulin gene variable number of tandem repeat-associated risk for juvenile onset type 1 diabetes. Tissue Antigens 2004, 63:568-571.
78. Estany J., Tor M., Villalba D., et al. Association of CA repeat polymorphism at intron 1 of insulin-like growth factor (IGF-I) gene with circulating IGF-I concentration, growth and fatness in swine. Physiol Genomics 2007, 31:236-243.
79. te Velde S.J., van Rossum E.F., Voorhoeve P.G., et al. An IGF-I promoter polymorphism modifies the relationships between birth weight and risk factors for cardiovascular disease and diabetes at age 36. BMC Endocr Disord 2005, 5:5.
80. Rietveld I., Hofman A., Pols H.A., et al. An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance. Eur J Endocrinol 2006, 154:715-721.
81. Rietveld I., Ikram M.K., Vingerling J.R., et al. An IGF-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006, 55:2387-2391.
82. Heald A.H., Stephens R.H., McElduff P., et al. Polymorphisms in insulin-like growth factor binding protein-1 (IGFBP-1) are associated with altered circulating IGF-I and lower mass index in type-2 diabetes mellitus. Endo Abs 2006, 11:413.
83. Stephens R.H., McElduff P., Heald A.H., et al. Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes 2005, 54:3547-3553.
84. Deal C., Ma J., Wilkin F., et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001, 86:124-180.
85. Kaplan R.C., Petersen A.K., Chen M.H., et al. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet 2011, 1093:1-11.
86. Zenobi P.D., Glatz Y., Keller A., et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994, 131:251-257.
87. Nakae J., Kato M., Murashita M., et al. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 1998, 83:542-549.
88. Morrow L.A., O'Brien M.B., Moller D.E., et al. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994, 79:205-210.
89. Moses A.C., Morrow L.A., O'Brien M., et al. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin resistant diabetes mellitus. Diabetes Res Clin Pract 1995, 28:S185-S194.
90. Savage M.O., Burren C.P., Blair J.C., et al. Growth hormone insensitivity: pathophysiology, diagnosis, clinical variation and future perspectives. Horm Res 2001, 2:32-35.
91. Woods K.A., Camacho-Hubner C., Bergman R.N., et al. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000, 85:1407-1411.
92. Quattrin T., Thrailkill K., Baker L., et al. Improvement in HbA1c without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin. rhIGF-I in IDDM Study Group. J Pediatr Endocrinol Metab 2001, 14:267-277.
93. Quattrin T., Thralkill K., Baker L., et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997, 20:374-380.
94. Carroll P.V., Christ E.R., Umpleby A.M., et al. IGF-I treatment in adults with type diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes 2000, 49:789-796.
95. Simpson H.L., Jackson N.C., Shoejaee-Moradie F., et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 2004, 89:425-432.
96. Williams R.M., Amin R., Shojaee-Moradie F., et al. The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with type 1 diabetes mellitus. Diabetologia 2003, 46:1203-1210.
97. Clemmons D.R., Moses A.C., McKay M.J., et al. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000, 85:1518-1524.
98. Clemmons D.R., Moses A.C., Sommer A., et al. Rh/IGF/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 2005, 15:265-274.
99. Saukkonen T., Shojaee-Moradie F., Williams R.M., et al. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 2006, 55:2365-2370.
100. Schalch D.S., Turman N.J., Marcsisin V.S., et al. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993, 77:1563-1568.
101. Moses A.C., Young S.C., Morrow L.A., et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996, 45:91-100.
102. Cusi K., DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 2000, 85:3077-3084.
103. Evidence from a dose ranging study that recombinant insulin-like growth factor-I (RhIGF-I) effectively and safely improves glycemic control in the noninsulin dependent diabetes mellitus. Diabetes 1996, 45:91-100. Rh in NIDDM Study Group.
104. RhIGF-I co therapy with insulin subgroup. RhIGF-I improves glucose control in insulin requiring type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose [abstract: 582]. Proceedings of the 5th Annual Meeting of The American Diabetes Association. San Antonio (TX), June 14, 1997.